Microgen announces Barbara Moorhouse to its Board as upcoming Non-Executive Director

– UK, London – Microgen Plc (LSE:MCGN), is pleased to announce the appointment of Barbara Moorhouse as a non-executive director of the Company with effect from 1 April 2017.

Barbara has over 25 years of senior UK and international management experience in both operating and financial roles. She has spent the major part of her career in the private sector, including holding Chief Finance Officer positions with the listed international software companies Kewill Systems plc and Scala Solutions NV. Her recent executive roles have included Chief Operating Officer of Westminster City Council, Director General at the Ministry of Justice and subsequently at the Department for Transport.

Barbara is currently a non-executive director of IDOX plc, Agility Trains and the Lending Standards Board. She is a former chair of OPM Group. Barbara is also a Trustee and Chair of Audit Committee at Guys and St Thomas’ Charity.

On her appointment to the Microgen Board, Barbara will become a member of the Company’s audit committee, remuneration committee and nomination committee. Barbara will also take on the role of audit committee chair following the retirement of Peter Bertram, the current chairman of the audit committee, at the Company’s AGM on 24 April 2017.

Ivan Martin, non-executive chairman of Microgen, commented: “We are very pleased to welcome Barbara onto the Microgen board. Her IT sector knowledge combined with insights from her extensive experience across both the private and public sectors will be invaluable as Microgen continues to expand.”

For more information : http://www.microgen.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

here, the original post =>